Next-gen melanoma drug, TAK-733, excels in lab tests

November 11, 2014

A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2. While the drug is conceived as a second-generation inhibitor in patients harboring the BRAF mutation, the study shows drug activity in melanoma models regardless of BRAF mutation status. Treated tumors shrunk up to 100 percent.

"The importance of this molecule is that it's a next-generation and highly potent inhibitor of a known melanoma pathway. It was highly effective against melanoma and the method of our study - using patient-derived tumor samples grown in mice - makes us especially optimistic that we should see similar results in the human disease," says John Tentler, PhD, investigator at the CU Cancer Center, associate professor at CU School of Medicine and one of the paper's lead authors.

Between fifty and sixty percent of human melanomas have an activating mutation in the gene BRAF. According to National Cancer Institute statistics, approximately 1 million people in the United States live with melanoma at any given time. In 2011, the U.S. Food and Drug Administration approved the drug vemurafenib to treat BRAF-mutant melanoma. But while response rates to vemurafenib are in the range of 80 percent for patients with the BRAF mutation, the duration of response if frequently limited to between 2 and 18 months.

"We're learning how to use existing drugs better, for example RAF along with MEK inhibitors to block both mutations and thus a common mechanism of resistance. But there is also room for improvement in the drugs themselves and we hope that TAK-733 could improve on the results of existing, approved MEK inhibitors," Tentler says.

Tentler points to the study's use of melanoma samples contributed by human patients and then grown in mice (called "patient-derived xenografts") as a better predictor of the drug's effectiveness in humans. A common alternative to patient-derived xenografts is to grow tumors in mice from cancer cells that have previously been cultured on plastic, sometimes having been derived from patients decades earlier. Previous work at the CU Program for the Evaluation of Targeted Therapy (PETT) lab and elsewhere shows that cultured cells adapt to their plastic environment, over time potentially losing genetic characteristics of the original cancer and also learning to grow in an environment optimized for plastic.

"When you grow cells on plastic and inject them into mice, that's not what a real tumor looks like. Instead, when you take a sample and grow it as a living tumor in a mouse model, you much more faithfully preserve the genetic and tissue landscape characteristics of the original tumor," Tentler says.

Tentler suggests that while approved BRAF inhibitors such as vemurafenib and MEK inhibitors such as trametinib have proved effective in melanoma, TAK-733 may offer substantial enough improvements to justify its continued development.

"There's always a need for better, more potent molecules," Tentler says.

University of Colorado Anschutz Medical Campus

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to